Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AtriCure (ATRC) Interest & Investment Income (2016 - 2025)

AtriCure (ATRC) has disclosed Interest & Investment Income for 16 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income rose 10.55% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, up 1.01% year-over-year, with the annual reading at $4.5 million for FY2025, 1.01% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $1.3 million at AtriCure, up from $1.2 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $1.4 million in Q4 2022, with the low at $76000.0 in Q2 2022.
  • Average Interest & Investment Income over 5 years is $758250.0, with a median of $946500.0 recorded in 2024.
  • The sharpest move saw Interest & Investment Income tumbled 66.91% in 2021, then soared 1178.57% in 2022.
  • Over 5 years, Interest & Investment Income stood at $112000.0 in 2021, then skyrocketed by 1178.57% to $1.4 million in 2022, then dropped by 27.3% to $1.0 million in 2023, then increased by 15.66% to $1.2 million in 2024, then grew by 10.55% to $1.3 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $1.3 million, $1.2 million, and $941000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.